Equity Overview
Price & Market Data
Price: $1.86
Daily Change: +$0.10 / 5.38%
Daily Range: $1.75 - $1.90
Market Cap: $3,041,992
Daily Volume: 35,662
Performance Metrics
1 Week: -15.68%
1 Month: -47.29%
3 Months: -47.89%
6 Months: -43.79%
1 Year: -81.73%
YTD: -55.94%
Details
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1 clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.